medigraphic.com
ISSN 2305-7939 (Electronic)

2017, Number 2

<< Back Next >>

RCU 2017; 6 (2)

Stauffer's syndrome in a patient with renal adenocarcinoma

Rodríguez CTL, Pérez PM, Borges SRS, Romero CD

Language: Spanish
References: 13
Page: 84-92
PDF size: 450.54 Kb.


ABSTRACT

Introduction: Stauffer's syndrome is a paraneoplasic manifestation consisting in non‐ metastatic hepatic failure which is present in different malignant diseases including renal adenocarcinoma. Objective: To present the clinical and therapeutic particularities of a patient with Stauffer's syndrome and renal adenocarcinoma. Case presentation: A 71 year‐ old male patient with history of arterial hypertension that came to the doctor with febricula, asthenia and loss of weight. On physical examination there was slight hepatomegaly. Haematic test showed elevated transaminases, direct bilirrubine, alkaline phosphatase and gamma‐ glutamil transpeptidase. Besides that, hipoalbuminemia, prolongation of protrombine time and accelerated erythrosedimentation were confirmed. Abdominal ultrasound and computed tomography showed the presence of a right renal tumor with malignant characteristics. Total transperitoneal nephrectomy was performed. During the transoperatory period there was profuse bleeding that required haemoderivative transfusions. A week after the operation, the levels of hepatic function were slightly lower, but three month after the operation these levels elevated again, corresponding with the appearance of hepatic, lung and abdominal lymph nodes metastasis. First received treatment with alpha 2 recombinant interferon, but when metastatic lesions were detected, the patient has palliative treatment with Avastín ®, according to oncologic protocol. Conclusions: When a patient has Stauffer's syndrome, the presence of renal adenocarcinoma must be suspected, as well as foresee the bad prognosis of the patient if after nephrectomy the indexes of hepatic function do not return to normal levels.


REFERENCES

  1. Stauffer MH. Nepfrogenic hepatoesplenomegaly. Gastroenterology. 1961;40:694.

  2. Blas Reina A, García Vázquez RA, Arriaga Aguilar J, Avechuco Carrillo ZG, Vázquez Gálvez A, León Duarte IL, et al. Tumor renal cromófobo y miomatosis uterina en paciente monorrena. Rev Mex Urol. 2013 [citado 10 Feb 2017];73(6):[aprox. 6 p.]. Disponible en: http://www.revistamexicanadeurologia.com/R evistas/2013/Espanol/Noviembre‐ Diciembre/07%20CC%20TUMOR%20RENAL%20 CROMOFOGO.pdf

  3. Hinostroza Yanahuaya J, Mon‐ Mon C, Ortega Marcos O, Herrero Berrón JC, Ortiz Libreros M, Vigil Medina A. Síndrome de Stauffer y carcinoma de próstata, dos casos en pacientes de hemodiálisis crónica. Nefrología. 2013 [citado 10 Feb 2017];33(5):[aprox 2 p.]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_artte xt&pid=S0211‐69952013000600024

  4. Campbell SC, Novick AC, Bukowski RM. Neoplams of the upper urinary tract. In Wein AJ, Kavoussi LR, Novick AC, Partin AW, Craig CA, editors. Campbell‐ Walsh Urology. 9th ed. Chapter 47 [CD‐ROM]. Philadelphia: Saunders Elsevier; 2007.

  5. Flavin K, Vasdev N, Ashead J, Lane T, Hanbury D, Nathan P, et al. Perioperative considerations in metastatic renal cell carcinoma. Rev Urol. 2016 [cited 2017 Feb 10];18(3):[about 10 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5102929/

  6. Caballero Vázquez A, Hidalgo Rico MA, Fernández Sánchez A. Afectación metastásica pulmonar de sarcoma renal de células claras en paciente de 70 años. Arch Bronconeumol. 2014 [citado 10 Feb 2017];50(10):[aprox. 4 p.]. Disponible en: http://www.archbronconeumol.org/es/afectaci on‐metastasica‐pulmonar‐sarcomarenal/ articulo/S0300289613003360/

  7. Moreno Palacios J, Wingartz Plata H, Pardo Belasteguigoitía P, Moreno Aranda J. Síndrome de Stauffer en cáncer de células transicionales de vejiga. Arch Esp Urol. 2011 [citado 10 Feb 2017];64(9):[aprox. 3 p.]. Disponible en: http://www.redalyc.org/pdf/1810/1810225190 08.pdf

  8. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: The many faces of renal cell carcinoma. Rev Urol. 2002 [cited 2017 Feb 10];4(4):[about 8 p.]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/169856 75

  9. Ates I, Kaplan M, Yilmaz N. A Stauffer's syndrome variant associated with renal cell carcinoma and thrombocytopenia. African J Urol. 2015 [cited 2017 Feb 10];21:[about 3 p.]. Available http://www.sciencedirect.com/science/article/ pii/S1110570415000983

  10. González García FJ, Hontoria Briso‐ Montiano JM, Sánchez Chapado M. Tumores malignos del parénquima renal. En: Castiñeiras Fernández J. Libro del Residente de Urología. Madrid: Gráficas Marte, S.L.; 2007. P. 441.

  11. Lane BR, Canter DJ, Rini BI, Uzzo RG. Cancer of the kidney. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. 10 th ed. Philadelphia: Wolters Klumer Health; 2015. p. 879.

  12. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa 2a for treatment of metastatic renal cell carcinoma: a randomized double ‐ blind phase III trial. Lancet. 2007 [cited 2017 Feb 10];370:[about 9 p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/181560 31

  13. Ares Valdés Y. Sobrevida de los pacientes con carcinoma renal avanzado tratados con interferón. Arch Esp Urol. 2009 [citado 10 Feb 2017];62(1):[aprox. 5 p.]. Disponible en: http://scielo.isciii.es/pdf/urol/v62n1/03.pdf




2020     |     www.medigraphic.com